A Phase 1 Dose-escalation Trial of SGN-75 in CD70-positive Non-Hodgkin Lymphoma or Renal Cell Carcinoma
This is a phase 1, open-label, dose-escalation clinical trial to evaluate the safety of SGN-75 in patients with CD70-positive relapsed or refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma.
Carcinoma, Renal Cell|Lymphoma, Non-Hodgkin
DRUG: SGN-75
Incidence of adverse events and laboratory abnormalities, Through 1 month following last dose
Best clinical response, Every 2 months|Duration of response, progression-free survival, Every 3 months until progression of disease or initiation of new treatment for cancer|Blood concentrations of SGN-75 and metabolites, Through 1 month following last dose|Incidence of antitherapeutic antibodies, Through 1 month following last dose
This is a phase 1, open-label, dose-escalation clinical trial to evaluate the safety of SGN-75 in patients with CD70-positive relapsed or refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma.